Trial Profile
Mechanisms Associated With Favorable Response to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- 22 May 2018 Status changed from recruiting to completed.
- 04 Oct 2017 Planned End Date changed from 30 Sep 2017 to 30 Sep 2018.
- 04 Oct 2017 Planned primary completion date changed from 30 Sep 2017 to 30 Sep 2018.